C9orf50 and neoplasm: C9ORF50 emerges as an exceptionally promising candidate for cancer therapy in this regard, exhibiting: (i) pronounced tumor specificity with negligible expression in immune cells and healthy tissues; (ii) predominant localization to the gastrointestinal tract, brain, and kidneys while being virtually absent in lymphoid organs (spleen, thymus) and other immune‐rich tissues (liver, lung) [52]; (iii) dispensability for normal development and physiological homeostasis; (iv) strong association with poor clinical outcomes.